Key Insights

Highlights

Success Rate

75% trial completion

Published Results

317 trials with published results (22%)

Research Maturity

671 completed trials (46% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

15.7%

228 terminated out of 1450 trials

Success Rate

74.6%

-11.9% vs benchmark

Late-Stage Pipeline

6%

85 trials in Phase 3/4

Results Transparency

47%

317 of 671 completed with results

Key Signals

317 with results75% success228 terminated

Data Visualizations

Phase Distribution

1,169Total
Not Applicable (167)
Early P 1 (21)
P 1 (550)
P 2 (346)
P 3 (77)
P 4 (8)

Trial Status

Completed671
Terminated228
Recruiting186
Unknown152
Active Not Recruiting122
Withdrawn48

Trial Success Rate

74.6%

Benchmark: 86.5%

Based on 671 completed trials

Clinical Trials (1450)

Showing 20 of 20 trials
NCT04726319Not ApplicableCompleted

Family History App in Personalized Medicine

NCT06246916Phase 3RecruitingPrimary

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

NCT07444606Phase 1Not Yet RecruitingPrimary

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

NCT04083599Phase 1Active Not Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

NCT07005297Not Yet RecruitingPrimary

Clinical Genetics Branch Eligibility Screening Survey

NCT07328516Enrolling By Invitation

Natural History Study of Early Life Exposures in Agriculture (ELEA)

NCT03804255Withdrawn

Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

NCT04851119Phase 1Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT05538130Phase 1RecruitingPrimary

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05355701Phase 1RecruitingPrimary

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT02332668Phase 1RecruitingPrimary

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT05600933Enrolling By Invitation

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT06060613Phase 1Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

NCT06463509CompletedPrimary

Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Melanoma

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT04314401Active Not Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

NCT00068003Enrolling By InvitationPrimary

Harvesting Cells for Experimental Cancer Treatments

NCT00001823Recruiting

Evaluation for NCI Surgery Branch Clinical Research Protocols

Scroll to load more

Research Network

Activity Timeline